Table 2.
The modified Newcastle–Ottawa quality assessment scale.
| Study | Sample size | Severe case | Mortality | Study type | Modified Newcastle-Ottawa quality assessment scale | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selection | Comparability | Outcome | Sum | |||||||||||
| S1 | S2 | S3 | S4 | C1 | O1.1 | O1.2 | O2 | O3 | ||||||
| Abou-Assi et al., 2002 | 156 | 5 | 14 | Prospective | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Albulushi et al., 2014 | 174 | 14 | 0 | Retrospective | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
| Gomez Beltran et al., 2013 | 24 | 1 | 0 | Retrospective | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| de-Madaria et al., 2014 | 403 | 28 | 17 | Prospective | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Dombernowsky et al., 2016 | 359 | nd | 13 | Retrospective | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 8 |
| Gompertz et al., 2012 | 128 | nd | 2 | Retrospective | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 6 |
| Gompertz et al., 2013 | 1367 | nd | 115 | Retrospective | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Gonzalez-Gonzalez et al., 2012 | 605 | nd | 30 | Prospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Gornik et al., 2013 | 1058 | 210 | 41 | Prospective | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Gürleyik et al., 2005 | 55 | 13 | 1 | Prospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Karpavicius et al., 2016 | 102 | 20 | 5 | Prospective | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Knoepfli et al., 2007 | 310 | 63 | 8 | Prospective | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Lautz et al., 2011 | 211 | nd | 0 | Retrospective | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Milheiro et al., 1995 | 91 | nd | 10 | Retrospective | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| Mole et al., 2016 | 2053 | 390 | 102 | Retrospective | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Muller et al., 2006 | 109 | 66 | 8 | Prospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Nijmeijer et al., 2013 | 622 | 119 | 20 | Prospective | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| Ocampo et al., 2015 | 854 | 140 | nd | Prospective | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Pant et al., 2014 | 55012 | nd | 509 | Retrospective | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Parniczky et al., 2016 | 600 | 53 | 17 | Prospective | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 9 |
| Radenkovic et al., 2009 | 91 | 24 | 8 | Prospective | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Rashidi and Røkke, 2016 | 670 | 43 | 37 | Prosp and Retrosp | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 8 |
| Spanier et al., 2013 | 78257 | nd | 9515 | Retrospective | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Uomo et al., 2007 | 1173 | 167 | 36 | Prospective | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| De Waele et al., 2007 | 40 | 14 | 6 | Retrospective | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 7 |
| Wang et al., 2015 | 120 | 31 | 13 | Retrospective | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| Ho et al., 2015 | 12284 | 765 | nd | Retrospective | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 4 |
| Weitz et al., 2016 | 346 | 21 | 12 | Retrospective | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Wu et al., 2008 | 36178 | nd | 569 | Retrospective | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Yeung et al., 1996 | 43 | nd | 1 | Retrospective | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 6 |
| Yue et al., 2015 | 169 | 68 | nd | Prospective | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
| Zhang et al., 2016 | 974 | 223 | 58 | Retrospective | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 8 |
| Zuidema et al., 2014 | 64 | 11 | 3 | Prospective | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 |
Ranks in three categories (green-1: low risk; red-0: high risk, yellow-0: unclear risk) are shown. S1, non-selected etiology AP; S2, all participants have an AP diagnosis; S3, AP diagnosis is confirmed using the latest guidelines; S4, non-selected severity cases. C1: comparability defined by exact age ranges in years. O1.1, severity assigned according to the latest guidelines; O1.2, described mortality (in-hospital and pancreas-related); O2–O3, adequate follow-up for outcome occurrence morality and severity.